Karissa Whiting

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4637617/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. Journal of Clinical Oncology, 2022, 40, 1312-1322.	1.6	42
2	CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes. Radiology, 2022, 303, 664-672.	7.3	28
3	Percutaneous Cryoablation Provides Disease Control for Extra-Abdominal Desmoid-Type Fibromatosis Comparable with Surgical Resection. Annals of Surgical Oncology, 2022, 29, 640-648.	1.5	17
4	Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. Clinical Cancer Research, 2022, 28, 45-56.	7.0	13
5	Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors. Journal of Immunotherapy, 2021, 44, 248-253.	2.4	10
6	A phase II trial of durvalumab and tremelimumab in metastatic, nonâ€urothelial carcinoma of the urinary tract. Cancer Medicine, 2021, 10, 1074-1083.	2.8	10
7	Evaluation and Verification of the Global Rapid Identification of Threats System for Infectious Diseases in Textual Data Sources. Interdisciplinary Perspectives on Infectious Diseases, 2016, 2016, 1-5.	1.4	8
8	Intensityâ€nodulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. Cancer, 2021, 127, 4161-4170.	4.1	8
9	Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. JCO Precision Oncology, 2022, , .	3.0	6
10	Clinical and Genomic Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS) Tj ETQq0 0 0 Diseases, 2022, 75, e774-e782.	rgBT /Ove 5.8	rlock 10 Tf 5 5
11	Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2022, 28, 4267-4277.	7.0	4
12	A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma. Blood Advances, 2022, , .	5.2	3
13	The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant. Bone Marrow Transplantation, 2021, 56, 2749-2754.	2.4	0
14	Synchronous and metachronous bilateral breast cancer among women with a history of lobular	2.5	0

carcinoma in situ. Breast Cancer Research and Treatment, 2022, , .